Skip to main content
x
About searching

Search results

  1. Chia Tai keeps the TGF-β faith

    … China ph1/2 in solid tumours; initial data at ASCO 2024: 6% ORR HCB301 HanchorBio Fusion …

    - 09/17/2025 - 09:48

  2. World Lung 2025 – Candel looks to a new agla-vec use

    … that's relevant since this same study disappointed at ASCO 2024 when a poster revealed an ORR of just 11% among 45 …

    - 09/12/2025 - 17:50

  3. Novocure’s Lunar eclipse

    … NSCLC + supportive care, vs supportive care Data at ASCO 2024: hit primary endpoint, time to intracranial …

    - 09/02/2025 - 15:02

  4. Ivonescimab back in tune

    … disclosure highly relevant to the global trial. At ASCO 2024 Harmoni-A showed a highly statistically …   Harmoni-A OS data   Source: ASCO 2024.   Akeso’s latest disclosure, which was …

    - 09/01/2025 - 13:38

  5. Arcus reaches the end of the road for etrumadenant

    … a path forward based on the phase 1/2 Arc-9 trial, which at ASCO 2024 showed a 73% reduction in the risk of death with … January 2024 investment reshuffle.   Arc-9 data at ASCO 2024 Source: company presentation. …

    - 08/07/2025 - 18:22

  6. 5,000 patients later Roche scraps its TIGIT

    … cards since the molecule put up dismal phase 1 data at ASCO 2024 , so the main surprise will be what took Roche so … RG6614 USP1 inhibitor (ex KSQ) Disappointed in ph1 at ASCO 2024 RO7589831/ RG6457 Werner helicase …

    - 07/28/2025 - 17:18

  7. Sino takes out the rest of Merck’s partner

    … China ph1/2 in solid tumours (monotx & combos); data at ASCO 2024: 13% ORR (2/16) with monotx LM-168 …

    - 07/18/2025 - 13:28

  8. AbbVie's telisotuzumab conjugate take two

    … relapsed colorectal cancer, where first-in-human data at ASCO 2024 showed 2.4mg/kg or higher dose scoring a 38% ORR …

    - 09/09/2025 - 13:04

  9. AbbVie gets a cMet niche

    … 2nd-line+ solid tumours, incl CRC (+/- Avastin) Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …

    - 05/19/2025 - 10:52

  10. Qilu nabs a new B7-H3 contender

    … In a Chinese phase 1/2 solid tumour trial reported at ASCO 2024, MHB088C produced a 61% overall response rate …

    - 05/13/2025 - 16:22